Pages that link to "Q44484456"
Jump to navigation
Jump to search
The following pages link to NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma (Q44484456):
Displaying 50 items.
- HDACs and the senescent phenotype of WI-38 cells (Q24810847) (← links)
- Clinical use and applications of histone deacetylase inhibitors in multiple myeloma (Q26745930) (← links)
- Panobinostat for the treatment of multiple myeloma: the evidence to date (Q26778674) (← links)
- Novel agents for multiple myeloma to overcome resistance in phase III clinical trials (Q26822754) (← links)
- Bioactive heterocycles containing endocyclic N-hydroxy groups (Q27025241) (← links)
- Novel therapeutic strategies for multiple myeloma (Q28081590) (← links)
- From bench to bedside: lessons learned in translating preclinical studies in cancer drug development (Q28533949) (← links)
- Anticancer activities of histone deacetylase inhibitors (Q29616624) (← links)
- A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma (Q33410997) (← links)
- Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma (Q33854012) (← links)
- Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. (Q34194704) (← links)
- New insights into the treatment of multiple myeloma with histone deacetylase inhibitors (Q34224278) (← links)
- Histone modification enzymes: novel targets for cancer drugs (Q34322087) (← links)
- The DAC system and associations with multiple myeloma. (Q34414447) (← links)
- Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma (Q34441748) (← links)
- Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. (Q34488424) (← links)
- Antitumor action of a novel histone deacetylase inhibitor, YF479, in breast cancer (Q34528291) (← links)
- The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma (Q34602263) (← links)
- HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma (Q34707183) (← links)
- New insights, recent advances, and current challenges in the biological treatment of multiple myeloma (Q34773850) (← links)
- The role of DNA synthesis imaging in cancer in the era of targeted therapeutics (Q34907192) (← links)
- Augmenting antitumor immune responses with epigenetic modifying agents (Q35048054) (← links)
- Apoptotic pathways activated by histone deacetylase inhibitors: implications for the drug-resistant phenotype (Q35595410) (← links)
- Histone deacetylase inhibitors in clinical development (Q35609717) (← links)
- Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress (Q35750893) (← links)
- Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma (Q35764582) (← links)
- The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy (Q36087855) (← links)
- Targeted therapy in multiple myeloma (Q36108614) (← links)
- Targeting signalling pathways for the treatment of multiple myeloma (Q36150866) (← links)
- Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach (Q36177918) (← links)
- Differential effects of histone deacetylase inhibitors in tumor and normal cells-what is the toxicological relevance? (Q36179533) (← links)
- Histone deacetylase inhibitors: insights into mechanisms of lethality (Q36219726) (← links)
- Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates (Q36372894) (← links)
- Advances in oral therapy for multiple myeloma. (Q36436240) (← links)
- Targeting epigenetic abnormalities with histone deacetylase inhibitors (Q36529933) (← links)
- Lenalidomide in multiple myeloma (Q36573818) (← links)
- Investigational treatments for multiple myeloma (Q36654336) (← links)
- The evolving role of lenalidomide in the treatment of hematologic malignancies (Q36739807) (← links)
- Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets (Q36889961) (← links)
- The aggresome pathway as a target for therapy in hematologic malignancies (Q36984494) (← links)
- Preclinical studies of novel targeted therapies (Q36998210) (← links)
- From the bench to the bedside: emerging new treatments in multiple myeloma (Q37028598) (← links)
- Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors. (Q37083880) (← links)
- Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications (Q37201984) (← links)
- Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies (Q37226511) (← links)
- Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors (Q37284812) (← links)
- Targeting Waldenstrom macroglobulinemia with histone deacetylase inhibitors (Q37326878) (← links)
- Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma (Q37379984) (← links)
- Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. (Q37426386) (← links)
- Targeted therapies in multiple myeloma (Q37431609) (← links)